Пацієнти з високим ризиком розвитку венозних трофічних виразок після епізоду ТГВ ... Деякі аспекти патогенезу, чи можливо прогнозувати виникнення трофічних порушень?
DOI:
https://doi.org/10.24144/2415-8127.2020.61.114-129Анотація
ТГВ проявляється важкими порушеннями в системі гемостазу і, в більшості випадків, супроводжується розвит- ком ПТС. Патогенетичні зміни, що виникають у пацієнтів із ПТС у системі гемостазу і системі мікроциркуляторного русла нижніх кінцівок в сукупності є постійним підтримучим механізмом, що викликає не тільки утворення і про- гресування трофічних порушень, але і виникнення самої виразки. Відповідно до літературних даних, при наявності певних факторів ризику, таких як наявність в анамнезі венозної тромбоемболії, раніше існуючого варикозного розширення вен нижніх кінцівок, чоловічої статі, а також ожиріння незалежно збільшується ризик розвитку ПТС виразки через 1 рік. Виявлення таких пацієнтів з урахуванням факторів ризику, а також беручи до уваги можливість розвитку виражених патогенетичних порушень, необхідно для призна- чення патогенетично спрямованого лікування із застосуванням – сулодексиду, призначення якого може не тільки запобігти рецидивам ТГВ, а й з огляду на фактори ризику, запобігти розвитку трофічних порушень, зокрема трофічних виразок.
Посилання
Rabinovich A., Kahn S.R. How I treat the postthrombotic syndrome Blood. 2018;131(20):2215-2222.
Jeffrey J. Farrell, Sutter C., Tavri S., Patel S. Incidence and interventions for post-thrombotic syndrome Cardiovasc Diagn Ther 2016;6(6):623-631
Polak M., Siudut J., Plens K., Undas A. Prothrombotic clot properties can predict venous ulcers in patientsfollowing deep vein thrombosis: a cohort studyJournal of Thrombosis and Thrombolysis (2019) 48:603–609.
Galanaud J., Bertoletti L., Amitrano M., Fernández-Capitán C. Predictors of Post-Thrombotic Ulcer after AcuteDVT: The RIETE Registry José María Pedrajas6 Vladimir Rosa7 Manuel Barrón8 Alicia Lorenzo9 Olga Madridano10Isabelle Quéré1 Susan R. Kahn11 Paolo Prandoni12 Manuel Monreal13 for the RIETE registry Investigators.
Yamaki T. Post-thromboticsyndrome – Recentaspectsofprevention,diagnosis and clinicalmanagement /ReviewsinVascularMedicine6-7(2016)10–19.
Susan R. Kahn, MD, MSc, FRCPC, Chair; Anthony J. Comerota, MD; Mary Cushman, MD, MSc, FAHA; Natalie S. Evans, MD, MS; Jeffrey S. Ginsberg, MD, FRCPC; Neil A. Goldenberg, MD, PhD; Deepak K. Gupta, MD; Paolo Prandoni, MD, PhD; Suresh Vedantham, MD; M. Eileen Walsh, PhD, APN, RN-BC, FAHA; Jeffrey I. Weitz MD, FAHA;The Postthrombotic Syndrome: Evidence-BasedPrevention, Diagnosis, and Treatment StrategiesA Scientific Statement From the American Heart Associationon behalf of the American Heart Association Council on Peripheral Vascular Disease, Council onClinical Cardiology, and Council on Cardiovascular and Stroke NursingCirculation. 2014;130:1636-1661.
Jeffrey J. Farrell, Christopher Sutter, Sidhartha Tavri, Indravadan Patel Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, Ohio 44106, USAIncidence and interventions for postthrombotic syndromeContributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Jeffrey J. Farrell. Department of Radiology, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, Ohio 44106, USA. Cardiovasc Diagn Ther 2016;6(6):623-631
A. Ashrani1,J. A. HeitIncidence and Cost Burden of Post-Thrombotic Syndrome J Thromb Thrombolysis. 2009 November; 28(4): 465–476. doi:10.1007/s11239-009-0309-3.
Jean-Philippe Galanaud, Manuel Monreal, Susan R. Kahn Epidemiology of the post-thrombotic syndromeThrombosis Research 164 (2018) 100–109.
J.P. Galanaud, S.R. Kahn, The post-thrombotic syndrome: a 2012 therapeutic update,Curr. Treat. Options Cardiovasc. Med. 15 (2013) 153–163.
LA GHEUCÃ-SOLOVÃSTRU*,**, DAN VÂÞÃ*,**, LAURA STÃTESCU*,**,ELENA PORUMBANDRESE*,**, ALINA STÎNCANU**, ADRIANA-IONELA PÃTRAªCU*,**,IOANA-ALINA GRÃJDEANU*SULODEXID FOR THE TREATMENT AND PREVENTION OF POST-THROMBOTIC SYNDROMEDermatoVenerol. (Buc.), 63(2): 17–22.
Atul Jain, Adam S.Cifu. Prevention, Diagnosis and Treatment of Postthrombotic Syndrome. JAMA. 2016;315(10).
Susan R. Kahn, Jean-Philippe Galanaud, Suresh Vedantham, Jeffrey S. Ginsberg. Guidance for the prevention andtreatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016; 41:144–153.
Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Definition of post-thrombotic syndrome of the leg foruse in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7:879–883.
MacDougall DA, Feliu AL, Boccuzzi SJ,Lin J. Economic burden of deep-veinthrombosis, pulmonary embolism, andpost-thrombotic syndrome. Am J HealthSyst Pharm. 2006;63(20, suppl 6):S5–S15.
Kachroo S, Boyd D, Bookhart BK, et al. Qualityof life and economic costs associated withpostthrombotic syndrome. Am J Health Syst Pharm. 2012;69(7):567–572.
Kahn SR, Hirsch A, Shrier I. Effect of postthromboticsyndrome on health-relatedquality of life after deep venous thrombosis. Arch Intern Med. 2002;162(10):1144–1148.
Kahn SR, M’Lan CE, Lamping DL, Kurz X,Be´ rard A, Abenhaim L; Veines Study Group.The influence of venous thromboembolism on quality of life and severity of chronic venousdisease. J Thromb Haemost. 2004;2(12):2146–2151.
Roberts LN, Patel RK, Donaldson N, Bonner L,Arya R. Post-thrombotic syndrome is an independentdeterminant of health-related quality of life following both first proximal anddistal deep vein thrombosis. Haematologica. 2014;99(3):e41–e43.
Tick LW, Doggen CJ, Rosendaal FR, et al.Predictors of the post-thrombotic syndromewith non-invasive venous examinations inpatients 6 weeks after a first episode of deepvein thrombosis. J Thromb Haemost. 2010;8(12):2685–2692.
Labropoulos N, Waggoner T, Sammis W,Samali S, Pappas PJ. The effect of venousthrombus location and extent on the development of post-thrombotic signs and symptoms.J Vasc Surg. 2008;48(2):407–412.
Stain M, Scho¨ nauer V, Minar E, et al. The postthrombotic syndrome: risk factors and impacton the course of thrombotic disease. J ThrombHaemost. 2005;3(12):2671–2676.
Enden T, Resch S, White C, Wik HS, Kløw NE,Sandset PM. Cost-effectiveness of additionalcatheterdirected thrombolysis for deep vein thrombosis. J Thromb Haemost. 2013;11(6):1032–1042.
Roumen-Klappe EM, den Heijer M, van UumSH, van der Ven-Jongekrijg J, van der Graaf F,Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. J VascSurg. 2002;35(4):701–706.
Deatrick KB, Elfline M, Baker N, et al.Postthrombotic vein wall remodeling: preliminaryobservations. J Vasc Surg. 2011;53(1):139–146. 26. Johnson BF, Manzo RA, Bergelin RO,Strandness DE Jr. Relationship betweenchanges in the deep venous system andthe development of the postthromboticsyndrome after an acute episode of lowerlimb deep vein thrombosis: a one- tosix-year follow-up. J Vasc Surg. 1995;21(2):307–313
Schulman S, Granqvist S, Juhlin-Dannfelt A, et al. Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase. Acta Med Scand1986;219:349–57.
McLafferty RB, Moneta GL, Passman MA, et al. Late clinical and hemodynamic sequelae of isolated calf vein thrombosis. J Vasc Surg 1998;27:50-6; discussion 56–7.
Susan R. Kahn, Jean-Philippe Galanaud, Suresh Vedantham, Jeffrey S. Ginsberg. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016; 41:144–153.
Rabinovich A, Cohen JM, Kahn SR. The predictive valueof markers of fibrinolysis and endothelial dysfunction in the postthrombotic syndrome. A systematic review. Thromb Haemost2014;111(6):1031–1040
Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005;3:718–23.
van Dongen CJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005;3:939–42.
Tick LW, Doggen CJ, Rosendaal FR, et al.Predictors of the post-thrombotic syndromewith non-invasive venous examinations in patients 6 weeks after a first episode of deepvein thrombosis. J Thromb Haemost. 2010;8(12):2685–2692.
Galanaud JP, Holcroft CA, Rodger MA, et al.Predictors of post-thrombotic syndrome in apopulation with a first deep vein thrombosisand no primary venous insufficiency. J ThrombHaemost. 2013;11(3):474–480.
Ten Cate-Hoek AJ, Ten Cate H, Tordoir J,Hamulya´ k K, Prins MH. Individually tailoredduration of elastic compression therapy inrelation to incidence of the postthromboticsyndrome. J Vasc Surg. 2010;52(1):132–138.
Tick LW, Kramer MH, Rosendaal FR, FaberWR, Doggen CJ. Risk factors for postthromboticsyndrome in patients with a firstdeep venous thrombosis. J Thromb Haemost.2008;6(12):2075–2081.
Kahn SR, Shrier I, Julian JA, et al. Determinantsand time course of the postthrombotic syndromeafter acute deep venous thrombosis.Ann Intern Med. 2008;149(10):698–707.
van Dongen CJ, Prandoni P, Frulla M,Marchiori A, Prins MH, Hutten BA. Relationbetween quality of anticoagulant treatmentand the development of the postthromboticsyndrome. J Thromb Haemost. 2005;3(5):939–942.
Stain M, Scho¨ nauer V, Minar E, et al. The postthromboticsyndrome: risk factors and impacton the course of thrombotic disease. J ThrombHaemost. 2005;3(12):2671–2676.
(1). Chitsike RS, Rodger MA, Kovacs MJ, et al. Riskof post-thrombotic syndrome after subtherapeuticwarfarin anticoagulation for a firstunprovoked deep vein thrombosis: resultsfrom the REVERSE study. J Thromb Haemost.2012;10(10):2039–2044.
Hull RD, Liang J, Townshend G. Long-termlow-molecular-weight heparin and the postthromboticsyndrome: a systematic review.Am J Med. 2011;124(8):756–765.
Cheung YW, Middeldorp S, Prins MH, et al;Einstein PTS Investigators Group. Postthromboticsyndrome in patients treated withrivaroxaban or enoxaparin/vitamin K antagonistsfor acute deep-vein thrombosis. A posthoc analysis. Thromb Haemost. 2016;116(4):733–738.
Jeraj L, Jezovnik MK, Poredos P. Rivaroxabanversus warfarin in the prevention of postthromboticsyndrome. Thromb Res. 2017;157:46–48.
Prandoni P, Lensing AWA, Prins MH, et al.Below-knee elastic compression stockings toprevent the postthrombotic syndrome: a randomized, controlled trial. Ann Intern Med.2004;141(4):249–256.
Prandoni P, Lensing AWA, Cogo A, et al. Thelong-term clinical course of acute deep venousthrombosis. Ann Intern Med. 1996;125(1):1–7.
Roberts LN, Patel RK, Chitongo PB, Bonner L,Arya R. Presenting D-dimer and early symptomseverity are independent predictors forpost-thrombotic syndrome following a firstdeep vein thrombosis. Br J Haematol. 2013;160(6):817–824.
Prandoni P, Frulla M, Sartor D, Concolato A,Girolami A. Vein abnormalities and the postthromboticsyndrome. J Thromb Haemost. 2005;3(2):401-402.
Vedovetto V, Dalla Valle F, Milan M,Pesavento R, Prandoni P. Residual veinthrombosis and trans-popliteal reflux in patientswith and without the post-thromboticsyndrome. Thromb Haemost. 2013;110(4):854–855.
Sartori M, Favaretto E, Cini M, Legnani C,Palareti G, Cosmi B. D-dimer, FVIII andthrombotic burden in the acute phase of deepvein thrombosis in relation to the risk of postthromboticsyndrome. Thromb Res. 2014; 134(2):320–325.
Prandoni P, Lensing AWA, Prins MH, et al. Theimpact of residual thrombosis on the longtermoutcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost. 2015;41(2):133–140.
Haenen JH, Janssen MC, van Langen H, et al.The postthrombotic syndrome in relation tovenous hemodynamics, as measured by means of duplex scanning and strain-gaugeplethysmography. J Vasc Surg. 1999;29(6):1071–1076.
Haenen JH, Janssen MC, Wollersheim H, et al.The development of postthrombotic syndromein relationship to venous reflux and calf muscle pump dysfunction at 2 years after theonset of deep venous thrombosis. J Vasc Surg.2002;35(6):1184–1189.
Yamaki T, Nozaki M, Sakurai H, Takeuchi M,Soejima K, Kono T. High peak reflux velocity inthe proximal deep veins is a strong predictor of advanced post-thrombotic sequelae.J Thromb Haemost. 2007;5(2):305–312.
van Rij AM, Hill G, Krysa J, et al. Prospectivestudy of natural history of deep vein thrombosis:early predictors of poor late outcomes. Ann Vasc Surg. 2013;27(7):924–931.
Rabinovich A, Cohen JM, Cushman M, et al.Inflammation markers and their trajectoriesafter deep vein thrombosis in relation to risk of post-thrombotic syndrome. J ThrombHaemost. 2015;13(3):398–408.
Roumen-Klappe EM, Janssen MC, Van RossumJ, et al. Inflammation in deep vein thrombosisand the development of post-thromboticsyndrome: a prospective study. J ThrombHaemost. 2009;7(4):582–587.
Bouman AC, Smits JJ, Ten Cate H, Ten Cate-Hoek AJ. Markers of coagulation, fibrinolysisand inflammation in relation to postthrombotic syndrome. J Thromb Haemost.2012;10(8):1532–1538.
Shbaklo H, Holcroft CA, Kahn SR. Levels ofinflammatory markers and the development ofthe postthrombotic syndrome. ThrombHaemost. 2009;101(3):505–512.
de Franciscis S, Gallelli L, Amato B, et al.Plasma MMP and TIMP evaluation in patientswith deep venous thrombosis: could they have a predictive role in the development of postthromboticsyndrome? Int Wound J. 2016;13(6):1237–1245.
Kahn SR. How I treat postthrombotic syndrome.Blood. 2009;114(21):4624–4631.
Kahn SR, Ginsberg JS. Relationship betweendeep venous thrombosis and the postthromboticsyndrome. Arch Intern Med. 2004;164(1):17–26.
Prandoni P, Kahn SR. Post-thrombotic syndrome:prevalence, prognostication and needfor progress. Br J Haematol. 2009;145(3):286–295.
Villalta S, Bagatella P, Piccioli A, Lensing AWA,Prins MH, Prandoni P. Assessment of validityand reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis.1994;24(suppl 1):158a.
Nelzen O (2008) Prevalence of venous leg ulcer: the importanceof the data collection method. Phlebolymphology 15:143–150.
Lal BK (2015) Venous ulcers of the lower extremity: definition,epidemiology, and economic and social burdens. Semin Vasc Surg28:3–5. https ://doi.org/10.1053/j.semva scsur g.2015.05.002
Crawford JM, Lal BK, Durбn WN, Pappas PJ (2017) Pathophysiologyof venous ulceration. J Vasc Surg Venous Lymphat Disord5:596–605. https ://doi.org/10.1016/j.jvsv.2017.03.015 67. Lim CS, Baruah M, Bahia SS (2018) Diagnosis and managementof venous ulcers. BMJ 20:82–85. https ://doi.org/10.1177/1531003507 31321 8.
Kahn SR (2016) The post-thrombotic syndrome. Hematol Am SocHematol Educ Progr 1:413–418
O’Donnell TF, Passman MA, Marston WA et al (2014) Managementof venous leg ulcers: clinical practice guidelines ofthe Society for Vascular Surgery® and the American VenousForum. J Vasc Surg 60:3S–59S. https ://doi.org/10.1016/j.jvs.2014.04.049
Nelzen O (2008) Prevalence of venous leg ulcer: the importanceof the data collection method. Phlebolymphology 15:143–1504. Lal BK (2015) Venous ulcers of the lower extremity: definition,epidemiology, and economic and social burdens. Semin Vasc Surg28:3–5. https ://doi.org/10.1053/j.semva scsur g.2015.05.002.
Nelson EA, Adderley U (2016) Venous leg ulcers. BMJ. Clin Evid2016:1–36.
Abelyan G, Abrahamyan L, Yenokyan G (2018) A casecontrolstudy of risk factors of chronic venous ulceration inpatients with varicose veins. Phlebology 33:60–67. https ://doi.org/10.1177/02683 55516 68767 7.
Robertson L, Lee AJ, Gallagher K et al (2009) Risk factors forchronic ulceration in patients with varicose veins: a case controlstudy. J Vasc Surg 49:1490–1498. https ://doi.org/10.1016/j.jvs.2009.02.237.
Vlajinac H, Marinkovic J, Maksimovic M, Radak D (2014) Factorsrelated to venous ulceration: a crosssectional study. Angiology65:824–830. https ://doi.org/10.1177/00033 19713 50821 8.
Meulendijks AM, de Vries FMC, van Dooren AA et al (2018) Asystematic review on risk factors in developing a first time VenousLeg Ulcer. J Eur Acad Dermatology Venereol. 33(7):1241–1248.https ://doi.org/10.1111/jdv.15343.
Galanaud JP, Bertoletti L, Amitrano M et al (2018) Predictorsof post-thrombotic ulcer after acute DVT: the RIETE registry.Thromb Haemost 118:320–328. https ://doi.org/10.1160/TH17-08-0598.
Undas A, Ariлns RAS (2011) Fibrin clot structure and function:a role in the pathophysiology of arterial and venous thromboembolicdiseases. Arterioscler Thromb Vasc Biol 31:88–99. https ://doi.org/10.1161/ATVBA HA.111.23063 1.
Zabczyk M, Plens K, Wojtowicz W, Undas A (2017) Prothrombotic fibrin clot phenotype is associated with recurrent pulmonaryembolism after discontinuation of anticoagulant therapy. ArteriosclerThromb Vasc Biol 37:365–373. https ://doi.org/10.1161/ATVBA HA.116.30825 3.
Cieslik J, Mrozinska S, Broniatowska E, Undas A (2018) Alteredplasma clot properties increase the risk of recurrent deep veinthrombosis: a cohort study. Blood 131:797–807. https ://doi.org/10.1182/blood -2017-07- 79830 6.
Sumaya W, Wallentin L, James SK et al (2018) Fibrin clot properties independently predict adverse clinical outcome followingacute coronary syndrome: a PLATO substudy. Eur Heart J39:1078–1085. https ://doi.org/10.1093/eurhe artj/ehy01 3.
Siudut J, Grela M, Wypasek E et al (2016) Reduced plasma fibrinclot permeability and susceptibility to lysis are associated withincreased risk of postthrombotic syndrome. J Thromb Haemost 14:784–793. https //doi.org/10.1111/jth.13264.
Гомоляко І.В., Тумасова К.П., Швадчин І.О., Донцова Л.С., Клочкова Н.Є., Григорова І.В. Визначення діагностичної ефективності морфометричних параметрів // Вісник морфології. 2004. №10 (1). С. 35.
Герасимов И.Г. Функциональная неоднородность нейтрофилов // Клиническая лабораторная диагно- стика. 2006. №2. С.34-36. Ishikawa F. New biodefense strategies by Neutrophils // Arch. Immunol. Ther. Exp.- 2005. Vol. H.226–233.
Бухало В.А., Сисолятина Е.В., Нагурская Е.В. Регуляция врожденного иммунитета в очаге хрониче- ского воспаления // Иммунология. 2009. №3. С.184–188.
Гомоляко І.В, Тумасова К.П., Донцова Л.С, Самсонова Г.В., Швадчин І.О. Герпесвірусні інфекції і стан системи нейтрофільних гранулоцитів крові// Лабораторна діагностика, 2014.№3(65). С. 28–33.
Гомоляко І.В.,Тумасова К.П., Клочкова Н.Є., Самсонова Г.В., Калюжка А.С., Дубович Т.О. Прогно- зування післяопераційних ускладнень методом визначення індексу пошкодження системи нейтрофільних гранулоцитівкрові // Клінічна хірургія. 2014. № 1, 2. С. 85–88.
Чернуха Л.М. «Тяжелые формы хронической венозной недостаточности нижних конечностей. Пато- морфологическое обоснование «активной» хирургической тактики» // Вісник морфології Т.9. №2. С. 325- 327, 2003 р.
Schulman S, Lindmarker P, Holmstro¨m M,et al. Post-thrombotic syndrome, recurrence,and death 10 years after the first episode of venous thromboembolism treated with warfarinfor 6 weeks or 6 months. J ThrombHaemost. 2006;4(4):734–742.
Gould MK, Garcia DA, Wren SM et al. Prevention of VTE in non-orthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis. (American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 9th ed.) Chest 2012; 141(2 Suppl): e227S–e277S.
Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, (American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 9th ed.) Chest 2012; 141(2 Suppl):e278S–e325S.
Takashi Yamaki.Post-thrombotic syndrome – Recent aspects of prevention, diagnosis and clinical management. Reviews in Vascular Medicine 2016; (6-7):10–19.
C. Kearon, E.A. Akl, J. Ornelas et al. Antithrombotic therapy for VTE disease: CHEST J. Thromb. Haemost guideline and expert panel report. Chest 2016; 149:315–352.
Giuseppe M. Andreozzi, Angelo A. Bignamini et al.Sulodexide for the Prevention of Recurrent VenousThromboembolism. Circulation 2015;132:1891-1897.
Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. DrugDes Devel Ther2013;24(8):49–65.
Gaddi A., Galetti C., Illuminati B., Nascetti S. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996; 24 (5): 389–406.
Coccheri S., Scondotto G., Agnelli G. et al. Sulodexide in the tre-atment of intermittent claudication. Results of a randomized, doub-le-blind, multicentre, placebo-controlled study. Eur Heart J. 2002; 23 (13): 1057–65.
Condorelli M., Chiariello M., Dagianti A. et al. IPO-V2: a pro-spective, multicenter, randomized, comparative clinical investiga-tion of the effects of sulodexide in preventing cardiovascular acci-dents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994; 23 (1): 27–34
Errichi B., Cesarone M., Belcaro G. et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. An-giology. 2004; 55 (3): 243–9.
Cirujeda J., Granado P. A study on the safety, efficacy, and effici-ency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006; 57 (1): 53–64.
Cospite M., Milio G., Ferrara F. et al. Haemodynamic effects of sulodexide in post-thrombophlebitic syndromes. Acta Ther. 1992; 18: 149–61.
Luzzi R., Belcaro G., Dugall M. et al. The efficacy of sulodexide in the prevention of postthrombotic syndrome. Clin Appl Thromb Hemost. 2014; 20 (6): 594–9.
Adiguzel C., Iqbal O., Hoppensteadt D. et al. Comparative anti-coagulant and platelet modulatory effects of enoxaparin and sulo-dexide. Clin Appl Thromb Hemost. 2009; 15 (5): 501–11.
Mannello F., Ligi D., Raffetto J. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014; 33 (3): 236–42.
Broekhuizen L., Lemkes B., Mooij H. et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53 (12): 2646–55.
Saviano M., Maleti O., Liguori L. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tole-rability and dose-effect relationship of sulodexide in chronic ve-nous insufficiency. CurrMed Res Opin. 1993; 13 (2): 96–108.
Coccheri S., Scondotto G., Agnelli G. et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002; 87 (6): 947–52.
Munari A., Cervera L. Inflammation, Metalloproteinases, Chronic Venous Disease and Sulodexide. J Cardiovasc Dis Diagn 3: 203. doi:10.4172/2329-9517.1000203.
Hoppensteadt D., Fareed J. Pharmacological profile of sulodexi-de. Int Angiol 2014; 33: 229–235.
Mannello F., Ligi D., Raffetto J. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol 2014; 33: 236–242.
Frati-Munari A. Glicosaminoglicanos en las enfermedades vascu-lares. RevMexAngiol 2012; 40: 89–99.
Broekhuizen L., Lemkes B., Mooij H. et al. (2010) Effect of sulo-dexide on endothelial glycocalyx and vascular permeability in pa-tients with type 2 diabetes mellitus. Diabetologia 53: 2646–2655.
Ciszewicz M., Polubinska A., Antoniewicz A. Et al. Sulodexide sup-presses inflammation in human endothelial cells and prevents glu-cose cytotoxicity. Transl Res 2009; 153: 118–123.
Suminska-Jasinska K., Polubinska A., Ciszewicz M. Et al. Sulode-xide reduces senescence-related changes in human endothelial cells. Med Sci Monit 2011; 17: CR222–226.
Mannello F., Ligi D., Canale M., Raffetto J. Sulodexide down-re-gulates the release of cytokines, chemokines, and leukocyte colo-ny stimulating factors from human macrophages: role of glycosa-minoglycans in inflammatory pathways of chronic venous dis-ease.CurrVascPharmacol 2014; 12: 173–185.
Carroll BJ, Piazza G, Goldhaber SZ.Sulodexide in venous disease. J Thromb Haemost 2019; 17:31–8.
Inflammation, Metalloproteinases, Chronic Venous Disease and Sulodexide Alberto C. Frati Munari1* and Luis Fernando Flota Cervera2 1Department of Internal Medicine, Médica Sur Hospital, Puente de Piedra 150-1- 929, Toriello Guerra, Tlalpan, México D.F. 14050, México 2Director CEDIME Instituto Vascular, Calle 33 – 138, Mérida Yuc. 97129, México Journal of Cardiovascular Diseases &Diagnosis Munari and Cervera, J Cardiovasc Dis Diagn 2015, 3:4 DOI: 10.4172/2329-9517.1000203.
Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells Patrycja Sosińskaa Ewa Bauma Beata Maćkowiaka Magdalena Majb Katarzyna Sumińska-Jasińskaa Ryszard Staniszewskib Andrzej Bręborowicza Cell Physiol Biochem 2016;40:1005-1012 DOI: 10.1159/000453157 Published online: December 12, 2016.
Sulodexide reduces the inflammatory reaction and senescence of endothelial cells in conditions involving chronic venous disease Tomasz URBANEK 1 *, Zb igni ew KRASI NS KI 2, Katarzyna SUMINSKAJASINSKA 3, Ewa BA UM 4, Grazyna BOREJ-NOW IC KA 4, Beata BEGIER-KRAS!NSKA 5, lntemauonal Ang1ology 20 16 Apnl:35(2):140–7.
SulodexIde In the treatment of vaScular dISeaSe: ItS therapeutIc actIon on the endothelIum Karolina Jarząbek, Bożena Gabryel, Tomasz Urbanek Phlebological Review 2016; 24, 4: 51–59.
Scondotto G., Aloisi D., Ferrari P., Martini L. Treatment of ve-nous leg ulcers with sulodexide. Angiology 1999; 50: 883–889.
Coccheri S., Scondotto G., Agnelli G. et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002; 87: 947–952.
Kucharzewski M., Franec A., Hoziolek H. Treatment of venous leg ulcers with sulodexide. Phlebologie 2003; 32: 115–120.
Nelson E., Jones J. Venous leg ulcers. Clin Evid (Online); 2008.
Wu B., Lu J., Yang M., Xu T. Sulodexide for treating venous leg ulcers. Cochrane Database Syst Rev. 2016 Jun 2; 6: CD010694.Epub ahead of print.
